DLX-159

Last updated

DLX-159
Clinical data
Other namesDLX159
Routes of
administration 		Oral [1] [2]
Drug class Psychoplastogen; Serotonin 5-HT2B receptor antagonist; Other undisclosed actions [2]

DLX-159 is a putatively non-hallucinogenic psychoplastogen which is under development for the treatment of major depressive disorder and other psychiatric disorders. [1] [3] [2] It is taken by mouth. [1] [2]

The full mechanism of action of DLX-159 has yet to be disclosed. [1] [2] The drug shows psychoplastogenic effects in vitro and ex vivo . [2] These effects are blocked by the serotonin 5-HT2A receptor antagonst ketanserin as well as by the mTOR inhibitor rapamycin. [2] It also shows indications of psychoplastogenic effects in vivo in rodents. [2] Similarly to ketamine, DLX-159 shows rapid antidepressant-like effects in the forced swim test (FST) in rodents that are present within 24 hours of a single dose and are sustained for at least 3 days. [2] DLX-159 also reversed the depression-like phenotype induced by chronic interferon alpha exposure in rodents. [2] DLX-159 does not produce the head-twitch response, and hence does not appear to have psychedelic effects. [2]

DLX-159 shows no signs of cardiotoxicity. [2] It was assessed at the serotonin 5-HT2B receptor and was found to be an antagonist of this receptor. [2] Further data on the pharmacological activity of DLX-159, including its activities at various receptors and enzymes, will be published in the future. [2] The drug is orally bioavailable and crosses the blood–brain barrier. [2]

DLX-159 is under development by Delix Therapeutics. [1] [3] [2] As of January 2025, it is in the preclinical research stage of development. [1] [3] The drug was first described in the scientific literature by December 2024. [2] Its chemical structure does not yet seem to have been disclosed. [1]

See also

Related Research Articles

<span class="mw-page-title-main">Psychedelic drug</span> Hallucinogenic class of psychoactive drug

Psychedelics are a subclass of hallucinogenic drugs whose primary effect is to trigger non-ordinary mental states and a perceived "expansion of consciousness". Also referred to as classic hallucinogens or serotonergic hallucinogens, the term psychedelic is sometimes used more broadly to include various types of hallucinogens, such as those which are atypical or adjacent to psychedelia like salvia and MDMA, respectively.

<span class="mw-page-title-main">MBDB</span> Chemical compound

MBDB, also known as N-methyl-1,3-benzodioxolylbutanamine or as 3,4-methylenedioxy-N-methyl-α-ethylphenylethylamine, is an entactogen of the phenethylamine, amphetamine, and phenylisobutylamine families related to MDMA. It is known by the street names "Eden" and "Methyl-J".

<span class="mw-page-title-main">2,5-Dimethoxy-4-ethylamphetamine</span> Psychedelic drug

2,5-Dimethoxy-4-ethylamphetamine (DOET) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families. It is closely related to DOM and is a synthetic analogue of the naturally occurring phenethylamine psychedelic mescaline. The drug acts as a selective agonist of the serotonin 5-HT2 receptors, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors.

<span class="mw-page-title-main">Ariadne (drug)</span> Psychoactive phenethylamine drug

Ariadne, also known chemically as 4C-D or 4C-DOM, by its developmental code name BL-3912, and by its former tentative brand name Dimoxamine, is a little-known psychoactive drug of the phenethylamine, amphetamine, and phenylisobutylamine families. It is a homologue of the psychedelics 2C-D and DOM.

<span class="mw-page-title-main">2-Bromo-LSD</span> Chemical compound

2-Bromo-LSD, also known as BOL-148 or as bromolysergide, is a derivative of lysergic acid invented by Albert Hofmann, as part of the original research from which the closely related compound LSD was also derived. It is a non-hallucinogenic serotonin 5-HT2A receptor partial agonist, as well as acting at other targets, with psychoplastogenic and antidepressant-like effects in animals.

<span class="mw-page-title-main">Head-twitch response</span> Head movement in rodents upon 5-HT2A receptor activation

The head-twitch response (HTR), also sometimes known as wet dog shakes (WDS) in rats, is a rapid side-to-side head movement that occurs in mice and rats when the serotonin 5-HT2A receptor is activated. Serotonergic psychedelics like lysergic acid diethylamide (LSD) and psilocybin consistently induce the HTR in rodents. Because of this, the HTR is widely employed in scientific research as an animal behavioral model of hallucinogen effects and in the discovery of new psychedelic drugs.

<span class="mw-page-title-main">Tabernanthalog</span> Chemical compound

Tabernanthalog is a novel water-soluble, non-toxic azepinoindole analog of the psychoactive drug Tabernanthine first synthesized by Professor David E. Olson at UC Davis.

<span class="mw-page-title-main">DLX-001</span> Chemical compound

DLX-001, also known as AAZ-A-154 or as (R)-5-methoxy-N,N-dimethyl-α-methylisotryptamine, is a novel isotryptamine derivative which acts as a serotonin 5-HT2A receptor agonist discovered and synthesized by the lab of Professor David E. Olson at the University of California, Davis. It is being developed for the treatment of major depressive disorder and other central nervous system disorders.

Psychoplastogens are a group of small molecule drugs that produce rapid and sustained effects on neuronal structure and function, intended to manifest therapeutic benefit after a single administration. Several existing psychoplastogens have been identified and their therapeutic effects demonstrated; several are presently at various stages of development as medications including ketamine, MDMA, scopolamine, and the serotonergic psychedelics, including LSD, psilocin, DMT, and 5-MeO-DMT. Compounds of this sort are being explored as therapeutics for a variety of brain disorders including depression, addiction, and PTSD. The ability to rapidly promote neuronal changes via mechanisms of neuroplasticity was recently discovered as the common therapeutic activity and mechanism of action.

<span class="mw-page-title-main">ITI-1549</span> Non-hallucinogenic 5-HT2A agonist

ITI-1549 is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist which is under development for the treatment of mood disorders and other psychiatric disorders. In addition to acting at the serotonin 5-HT2A receptor, it is also an antagonist of the serotonin 5-HT2B receptor and an agonist of the serotonin 5-HT2C receptor. The drug's route of administration has not been specified.

(<i>R</i>)-MDMA Psychoactive drug taken by mouth

(R)-3,4-Methylenedioxy-N-methylamphetamine ((R)-MDMA), also known as (R)-midomafetamine or as levo-MDMA, is the (R)- or levorotatory (l-) enantiomer of 3,4-methylenedioxy-N-methylamphetamine (MDMA; midomafetamine; "ecstasy"), a racemic mixture of (R)-MDMA and (S)-MDMA. Like MDMA, (R)-MDMA is an entactogen or empathogen. It is taken by mouth.

BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications.

BMB-202 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and post-traumatic stress disorder (PTSD). It is taken by mouth. However, BMB-202 has also been evaluated by injection in preclinical studies.

LPH-48 is a selective serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of alcoholism. Its route of administration has not been specified.

<span class="mw-page-title-main">6-MeO-isoDMT</span> Serotonergic psychoplastogen

6-MeO-isoDMT, or 6-OMe-isoDMT, also known as 6-methoxy-N,N-dimethylisotryptamine, is a serotonin 5-HT2A receptor agonist, putative serotonergic psychedelic, and psychoplastogen of the isotryptamine group. It is the isotryptamine analogue of the psychedelic 5-MeO-DMT and is a positional isomer of the non-hallucinogenic psychoplastogen 5-MeO-isoDMT.

<span class="mw-page-title-main">5-MeO-isoDMT</span> Serotonergic psychoplastogen

5-MeO-isoDMT, or 5-OMe-isoDMT, also known as 5-methoxy-N,N-dimethylisotryptamine, is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen of the isotryptamine group. It is the isotryptamine analogue of the non-hallucinogenic 6-MeO-DMT and is a positional isomer of the psychedelic 6-MeO-isoDMT.

α-Methylisotryptamine Monoaminergic drug

α-Methylisotryptamine is a synthetic compound belonging to the tryptamine class, known for its psychoactive properties. As a structural analog of α-methyltryptamine (αMT), isoAMT exhibits entactogenic and psychedelic effects.

isoDMT Serotonergic drug

isoDMT, also known as N,N-dimethylisotryptamine, is a putatively non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen of the isotryptamine group. It is the isotryptamine homologue of dimethyltryptamine (DMT), a more well-known serotonergic psychedelic of the tryptamine family, and represents a small structural modification of DMT.

References

  1. 1 2 3 4 5 6 7 "DLX 159". AdisInsight. 15 January 2025. Retrieved 31 January 2025.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Rasmussen K, Agrawal R, Felts A, Leach P, Gillie D, Mungenast A, et al. (2024). "ACNP 63rd Annual Meeting: Poster Abstracts P1-P304: P252. DLX-159: A Novel, Next Generation, Non-Hallucinogenic Neuroplastogen With the Potential for Treating Neuropsychiatric Diseases" (PDF). Neuropsychopharmacology. 49 (S1): 65–235 (207–207). doi: 10.1038/s41386-024-02011-0 . ISSN   0893-133X. PMC   11627186 . PMID   39643633 . Retrieved 31 January 2025.
  3. 1 2 3 "Delving into the Latest Updates on DLX-159 with Synapse". Synapse. 23 January 2025. Retrieved 31 January 2025.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.